VERU News and Press, Veru Inc. From 06/07/23

2023-06-07 15:08:00 ET Veru ( NASDAQ: VERU ) has been upgraded by Jefferies from underperform to hold, due in part to the firm believing the stock was oversold and upcoming data from a Phase 2B clinical trial for Veru's breast cancer drug enobosarm. The investment bank said that...

2023-06-07 14:03:59 ET Veru Therapeutics ( NASDAQ: VERU ) has initiated a pivotal Phase 3 study of its drug candidate atacicept for the treatment of IgA nephropathy, an autoimmune kidney disorder also known as Berger's disease. The company will be testing the therapy on IgA neph...

MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the appointment of Erik Swenson...

2023-05-24 13:22:08 ET The Russell 3000 index will have a new look on June 26, after the market opens when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. At 2023 Russell indexes annual reconstitution, following consumer stocks wil...

MIAMI, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced that Mitchell Steiner, M.D., Cha...

2023-05-11 06:34:54 ET Veru press release ( NASDAQ: VERU ): Q2 GAAP EPS of -$0.48 misses by $0.15 . Revenue of $6.6M (-49.3% Y/Y) beats by $2.27M . Cash and cash equivalents were $23.5 million as of March 31, 2023 versus $80.2 million as of September 30, 2022. ...

Agreement reached with FDA on confirmatory Phase 3 clinical trial design for sabizabulin treatment of hospitalized COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS), including two planned interim efficacy analyses ENTADFI ® ...

2023-05-10 12:14:18 ET Veru ( NASDAQ: VERU ) is scheduled to announce Q2 earnings results on Thursday, May 11th, before market open. The consensus EPS Estimate is -$0.33 (-17.9% Y/Y) and the consensus Revenue Estimate is $4.33M (-54.9% Y/Y). Over the last 2 years, VERU...

Reached agreement with FDA on confirmatory Phase 3 clinical trial design in 408 subjects with primary endpoint of all-cause mortality at Day 60 Study to expand treatment population to include all WHO-4, WHO-5, and WHO-6 hospitalized adult COVID-19 patients at high risk for ARDS rega...

2023-05-03 09:12:09 ET Veru ( NASDAQ: VERU ) enters stock purchase agreement for the purchase of up to $100M with Lincoln Park Capital Fund or LPC, a Chicago-based institutional investor. Under the terms of the agreement, LPC has committed to purchase up to $100M stoc...